Abstract:Acute myeloid leukemia (AML) is a group of heterogeneous diseases. Abnormalities in genes that encode transcription factors and tyrosine kinases represent two classes of the most frequently detected genetic events in human AMLs. Recently, a new category of gene mutations associated with epigenetic regulation have also been proposed. Recurrent somatic mutations of DNMT3A were identified in 23 of 112 (20.5%) cases using exome sequencing technique. The DNMT3A mutants showed reduced enzymatic activity or aberrant affinity to histone H3 in vitro. Gene expression profiles and DNA methylation patterns showed some differences between patients with and without DNMT3A mutations. Notably, we found that members of HOXB genes were extensively upregulated with mutations of DNMT3A, and hypomethylation of certain CpG islands in the HOXB locus. DNMT3A mutations enabled 32D cells to acquire growth and survival advantage with and without IL3. Leukemias with DNMT3A mutations constituted a group of poor prognosis with elderly disease onset. These data suggest a contribution of aberrant DNA methyltransferase activity to the pathogenesis of acute monocytic leukemia and provides a useful new biomarker for relevant cases. We performed the study to systemically investigate the frequencies and the prognostic relevance of previously known genetic events and newly established molecular markers in a large series of 1,185 adult AML patients. In particular, we intent to stratify the AML patients who lacked cytogenetic prognostic markers into appropriate prognostic groups. Multivariate analysis identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event free survival (EFS), while bi-allelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in whole group and younger patients aged less than 60 years. Further studies will be focused on using different treatment strategies according to AML genotypes. Acute myeloid leukemia (AML) is a group of heterogeneous diseases. Abnormalities in genes that encode transcription factors and tyrosine kinases represent two classes of the most frequently detected genetic events in human AMLs. Recently, a new category of gene mutations associated with epigenetic regulation have also been proposed. Recurrent somatic mutations of DNMT3A were identified in 23 of 112 (20.5%) cases using exome sequencing technique. The DNMT3A mutants showed reduced enzymatic activity or aberrant affinity to histone H3 in vitro. Gene expression profiles and DNA methylation patterns showed some differences between patients with and without DNMT3A mutations. Notably, we found that members of HOXB genes were extensively upregulated with mutations of DNMT3A, and hypomethylation of certain CpG islands in the HOXB locus. DNMT3A mutations enabled 32D cells to acquire growth and survival advantage with and without IL3. Leukemias with DNMT3A mutations constituted a group of poor prognosis with elderly disease onset. These data suggest a contribution of aberrant DNA methyltransferase activity to the pathogenesis of acute monocytic leukemia and provides a useful new biomarker for relevant cases. We performed the study to systemically investigate the frequencies and the prognostic relevance of previously known genetic events and newly established molecular markers in a large series of 1,185 adult AML patients. In particular, we intent to stratify the AML patients who lacked cytogenetic prognostic markers into appropriate prognostic groups. Multivariate analysis identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event free survival (EFS), while bi-allelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in whole group and younger patients aged less than 60 years. Further studies will be focused on using different treatment strategies according to AML genotypes.

Role of DNA methyltransferase 3A in hematological malignancies

Dna Methyltransferases in Hematologic Malignancies

DNMT3A Gene Mutations in Acute Myeloid Leukemia——Review

DNMT3A gene mutations in acute myeloid leukemia]

Progress in combined treatments of myelodysplastic syndrome and acute myeloid leukemia based on DNA methyltransferase inhibitors

Aberrant DNA Methylation Associated with Silencing BNIP3 Gene Expression in Haematopoietic Tumours

Study on Methylation of P15ink4b Gene and Its Mechanisms in Patients with Myelodysplastic Syndrome and Leukemia.

Significance of targeting DNMT3A mutations in AML

Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia

Clinical characteristics and prognostic significance of DNA methylation regulatory gene mutations in acute myeloid leukemia

DNMT3A Mutation Leads to Hematopoietic Dysregulation.

Exome Sequencing Identifies Somatic Mutations of DNA Methyltransferase Gene DNMT3A in Acute Monocytic Leukemia.

Loss of Dnmt3b Accelerates MLL-AF9 Leukemia Progression

[Analysis of DNMT3a gene mutations in acute myelogenous leukemia]

DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming

Mutations in DNA Methyltransferases and Demethylases

Genetic and epigenetic changes contributing to leukemogenesis and prognostic impact in acute myeloid leukemia

Gene expression profiling of the DNMT3A R882 mutation in acute leukemia.

[The Expression of DNA Methyltransferase DNMT1, 3A and 3B in Acute Leukemia and Myelodysplastic Syndrome].

Biologico-clinical significance of DNMT3A variants expression in acute myeloid leukemia.

Structure-guided functional suppression of AML-associated DNMT3A hotspot mutations